Application of natural killer T cells in antitumor immunotherapy

Changwan Hong, Se-Ho Park

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

NKT cells are a unique subset of T cells that recognize glycolipid antigens presented by CD1d molecules. NKT cells have the potential to produce key cytokines of both Th1 and Th2 T cells and are involved in the control of several types of immune response. Furthermore, NKT cells perform spontaneous tumor immunosurveillance. Upon specific activation with α-GalCer, NKT cells show strong antitumor immune responses through direct cytotoxicity and indirect activation of a cascade of antitumor effector cells such as natural killer (NK) cells and CD8+ cytotoxic T cells. In addition to α-GalCer, many other CD1d ligands, including self and bacterial glycolipids and modified synthetic glycolipid antigens, have also been discovered. Structurally different glycolipid antigens have the distinct ability to activate NKT cells. Thus, it seems that we are now close to a position in which we can control the activation status of NKT cells; this makes NKT cells an ideal target of anticancer immunotherapies. Clinical trials with soluble α-GalCer or α-GalCer-pulsed dendritic cells aimed at in vivo reconstitution and activation of human NKT cells have provided both promising and challenging results. In this review, we discuss NKT-cell-mediated antitumor immune responses, as well as the early outcomes and implications of recent clinical studies.

Original languageEnglish
Pages (from-to)511-525
Number of pages15
JournalCritical Reviews in Immunology
Volume27
Issue number6
Publication statusPublished - 2007 Dec 1

Fingerprint

Natural Killer T-Cells
Immunotherapy
Glycolipids
CD1d Antigen
T-Lymphocytes
Antigens
Immunologic Monitoring
Th2 Cells
Synthetic Vaccines
T-Lymphocyte Subsets
Natural Killer Cells
Dendritic Cells
Clinical Trials
Cytokines
Ligands

Keywords

  • α-GalCer
  • Cancer
  • CD1d
  • Clinical study
  • Immunotherapy
  • NKT cells

ASJC Scopus subject areas

  • Immunology

Cite this

Application of natural killer T cells in antitumor immunotherapy. / Hong, Changwan; Park, Se-Ho.

In: Critical Reviews in Immunology, Vol. 27, No. 6, 01.12.2007, p. 511-525.

Research output: Contribution to journalArticle

@article{d2c14cba995d404fa5eb2c84c391f175,
title = "Application of natural killer T cells in antitumor immunotherapy",
abstract = "NKT cells are a unique subset of T cells that recognize glycolipid antigens presented by CD1d molecules. NKT cells have the potential to produce key cytokines of both Th1 and Th2 T cells and are involved in the control of several types of immune response. Furthermore, NKT cells perform spontaneous tumor immunosurveillance. Upon specific activation with α-GalCer, NKT cells show strong antitumor immune responses through direct cytotoxicity and indirect activation of a cascade of antitumor effector cells such as natural killer (NK) cells and CD8+ cytotoxic T cells. In addition to α-GalCer, many other CD1d ligands, including self and bacterial glycolipids and modified synthetic glycolipid antigens, have also been discovered. Structurally different glycolipid antigens have the distinct ability to activate NKT cells. Thus, it seems that we are now close to a position in which we can control the activation status of NKT cells; this makes NKT cells an ideal target of anticancer immunotherapies. Clinical trials with soluble α-GalCer or α-GalCer-pulsed dendritic cells aimed at in vivo reconstitution and activation of human NKT cells have provided both promising and challenging results. In this review, we discuss NKT-cell-mediated antitumor immune responses, as well as the early outcomes and implications of recent clinical studies.",
keywords = "α-GalCer, Cancer, CD1d, Clinical study, Immunotherapy, NKT cells",
author = "Changwan Hong and Se-Ho Park",
year = "2007",
month = "12",
day = "1",
language = "English",
volume = "27",
pages = "511--525",
journal = "Critical Reviews in Immunology",
issn = "1040-8401",
publisher = "Begell House Inc.",
number = "6",

}

TY - JOUR

T1 - Application of natural killer T cells in antitumor immunotherapy

AU - Hong, Changwan

AU - Park, Se-Ho

PY - 2007/12/1

Y1 - 2007/12/1

N2 - NKT cells are a unique subset of T cells that recognize glycolipid antigens presented by CD1d molecules. NKT cells have the potential to produce key cytokines of both Th1 and Th2 T cells and are involved in the control of several types of immune response. Furthermore, NKT cells perform spontaneous tumor immunosurveillance. Upon specific activation with α-GalCer, NKT cells show strong antitumor immune responses through direct cytotoxicity and indirect activation of a cascade of antitumor effector cells such as natural killer (NK) cells and CD8+ cytotoxic T cells. In addition to α-GalCer, many other CD1d ligands, including self and bacterial glycolipids and modified synthetic glycolipid antigens, have also been discovered. Structurally different glycolipid antigens have the distinct ability to activate NKT cells. Thus, it seems that we are now close to a position in which we can control the activation status of NKT cells; this makes NKT cells an ideal target of anticancer immunotherapies. Clinical trials with soluble α-GalCer or α-GalCer-pulsed dendritic cells aimed at in vivo reconstitution and activation of human NKT cells have provided both promising and challenging results. In this review, we discuss NKT-cell-mediated antitumor immune responses, as well as the early outcomes and implications of recent clinical studies.

AB - NKT cells are a unique subset of T cells that recognize glycolipid antigens presented by CD1d molecules. NKT cells have the potential to produce key cytokines of both Th1 and Th2 T cells and are involved in the control of several types of immune response. Furthermore, NKT cells perform spontaneous tumor immunosurveillance. Upon specific activation with α-GalCer, NKT cells show strong antitumor immune responses through direct cytotoxicity and indirect activation of a cascade of antitumor effector cells such as natural killer (NK) cells and CD8+ cytotoxic T cells. In addition to α-GalCer, many other CD1d ligands, including self and bacterial glycolipids and modified synthetic glycolipid antigens, have also been discovered. Structurally different glycolipid antigens have the distinct ability to activate NKT cells. Thus, it seems that we are now close to a position in which we can control the activation status of NKT cells; this makes NKT cells an ideal target of anticancer immunotherapies. Clinical trials with soluble α-GalCer or α-GalCer-pulsed dendritic cells aimed at in vivo reconstitution and activation of human NKT cells have provided both promising and challenging results. In this review, we discuss NKT-cell-mediated antitumor immune responses, as well as the early outcomes and implications of recent clinical studies.

KW - α-GalCer

KW - Cancer

KW - CD1d

KW - Clinical study

KW - Immunotherapy

KW - NKT cells

UR - http://www.scopus.com/inward/record.url?scp=38049065867&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38049065867&partnerID=8YFLogxK

M3 - Article

C2 - 18197797

AN - SCOPUS:38049065867

VL - 27

SP - 511

EP - 525

JO - Critical Reviews in Immunology

JF - Critical Reviews in Immunology

SN - 1040-8401

IS - 6

ER -